Infusion and Specialty Pharmacy Archives - Page 5 of 6

News

Demonstrating Excellence in Outcomes and Culture

$OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation$

Home / News / Infusion and Specialty Pharmacy / Page 5

Infusion and Specialty Pharmacy | News

Stay up to date with the latest innovations, company updates, and industry insights as we work to advance health and wellness for all.

OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation

Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya庐 (danicopan)

Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO庐 (selinexor)

Fabhalta (iptacopan) Now Available from Onco360 as the First FDA-Approved Oral Monotherapy Approved for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

TRUQAP™ (capivasertib) Now Available from Onco360

FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)

蘑菇视频

Demonstrating Excellence in Outcomes and Culture

Infusion and Specialty Pharmacy | News

Our Commitment to Quality

Join the 蘑菇视频 Team